Quantcast

Latest Metformin Stories

2011-05-02 14:18:00

SILVER SPRING, Md., May 2, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Tradjenta (linagliptin) tablets, used with diet and exercise, to improve blood glucose control in adults with Type 2 diabetes. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) People with Type 2 diabetes do not produce or respond normally to insulin, a hormone that regulates the amount of glucose in the blood. Over time, high blood glucose levels can increase the risk...

2011-04-28 14:44:55

NIH-funded researchers gain ground in treatment A specific form of vitamin E improved the most severe form of fatty liver disease in some children, according to a study funded by the National Institutes of Health. Results appear in the April 27 issue of the Journal of the American Medical Association. A previous study found vitamin E effective in some adults with the disease. Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease among U.S. children. NAFLD ranges in...

2011-04-27 06:20:26

(Ivanhoe Newswire) -- Contradicting previous data, the use of vitamin E or the diabetes drug metformin, was not superior to placebo on a measured outcome for treating nonalcoholic fatty liver disease in children and adolescents, according to a new study. "Coincident with the rise in prevalence of childhood and adolescent obesity over the past few decades, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in children in the United States,"...

2011-04-27 01:49:44

In contrast to previous preliminary data, use of vitamin E or the diabetes drug metformin was not superior to placebo on a measured outcome for treating nonalcoholic fatty liver disease in children and adolescents, according to a study in the April 27 issue of JAMA. "Coincident with the rise in prevalence of childhood and adolescent obesity over the past few decades, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in children in the United...

2011-04-07 13:54:16

New research suggests that several commonly prescribed drugs for type 2 diabetes may not be as effective at preventing death and cardiovascular diseases, such as heart attacks and stroke, as the oral anti-diabetic drug, metformin. Insulin secretagogues (ISs), such as glimepiride, glibenclamide (known as glyburide in the USA and Canada), gliclazide and tolbutamide, have been used to treat type 2 diabetes since the 1950-1970s, Nevertheless, the long-term risk associated with these drugs has...

2011-04-05 15:42:13

Research led by Warwick Medical School at the University of Warwick has found that Metformin, a drug treatment used to treat diabetes and also women with Polycystic Ovary syndrome (PCOS), may potentially provide protection against endometrial cancer. Endometrial cancer is the most common malignancy of the female genital tract and the fourth most common cancer in women in the UK and the US. Up to a third of PCOS women also have endometrial hyperplasia which, in turn predisposes these women to...

2011-03-16 08:30:00

NEW YORK, March 16, 2011 /PRNewswire/ -- Get content from Novo Nordisk A/S at: http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=b0000cc7-5c54-43cf-b48c-91f48bdc1a68&lr=ls Novo Nordisk announced on March 15 that the Chinese State Food and Drug Administration (SFDA) has approved Victoza® for the treatment of type 2 diabetes. Victoza® is the brand name for liraglutide, the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue...

2011-03-15 13:21:36

Johns Hopkins researchers examine newest medications, find they come up short An inexpensive type 2 diabetes drug that has been around for more than 15 years works just as well and has fewer side effects than a half-dozen other, mostly newer and more expensive classes of medication used to control the chronic disease, new Johns Hopkins research suggests. In their report, published online March 14 in the journal Annals of Internal Medicine, the Hopkins team found that metformin, an oral drug...

2011-03-04 04:01:00

PARIS and LONDON, March 4, 2011 /PRNewswire-FirstCall/ -- In the news release, "ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe" issued on 4 Mar 201108:00 GMT, by Bristol-Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would like to advise that the headline was incorrectly transmitted by PR Newswire and should have read "ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe in Type 2 Diabetes Patients With Moderate or Severe Renal...

2011-03-04 01:59:00

PARIS and LONDON, March 4, 2011 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (http://www.bms.com)(NYSE: BMY) and AstraZeneca (http://www.astrazeneca.com) (NYSE: AZN)today announced that the European Commission has approved a label update for ONGLYZA(R) (saxagliptin) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. The approved dosage for the patient group is a new once-daily 2.5 mg dose. ONGLYZA will be the first dipeptidyl...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related